Rheumatologic Manifestations of Patients With Type B Insulin Resistance
Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya +4 more
wiley +1 more source
Provision of foot health services for people with rheumatoid arthritis in New South Wales: a web-based survey of local podiatrists [PDF]
Background: It is unclear if podiatric foot care for people with rheumatoid arthritis (RA) in New South Wales (NSW) meets current clinical recommendations. The objective of this study was to survey podiatrists' perceptions of the nature of podiatric foot
A Blake +43 more
core +2 more sources
Seronegative spondyloarthropathies : a review : part I: classification and differential diagnosis [PDF]
The seronegative spondyloarthropathies comprise a group of non-rheumatoid disorders with similar clinical, laboratory and genetic features. Recognition of new clinical features has supported the notion that they all form part of a clinical spectrum ...
Borg, Andrew A. +2 more
core
High Healthcare Utilization Preceding Diagnosis with Juvenile Idiopathic Arthritis
Objective Though early diagnosis improves long‐term outcomes, Juvenile Idiopathic Arthritis (JIA) patients often experience prolonged, circuitous paths to diagnosis. To inform diagnostic improvement, we sought to characterize healthcare utilization in the year preceding diagnosis.
Anna Costello +5 more
wiley +1 more source
Trajectories of Physical Function in Canadian Children with Juvenile Idiopathic Arthritis
Objectives We describe trajectories of physical function in children newly diagnosed with juvenile idiopathic arthritis (JIA) and identify trajectories with persisting functional impairments and associated baseline characteristics. Methods We included patients enrolled in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry ...
Clare Cunningham +14 more
wiley +1 more source
Biologic treatments in rheumatoid arthritis and juvenile idiopathic arthritis [PDF]
A number of biological approaches to the management of inflammtory arthropathies have been explored. These include the development of IL-1 receptor antagonists and TNF antagonists. Four biological agents are currently marketed in Europe.
Borg, Andrew A.
core
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng +6 more
wiley +1 more source
Evolving Characteristics of Rheumatoid Arthritis Patients Receiving Primary Hip or Knee Arthroplasty: A 21-Year Single-Center Trend Analysis (2002-2022). [PDF]
Between 2002 and 2022, the volume of joint arthroplasties among patients with rheumatoid arthritis increased significantly, indicating a growing surgical demand over time. Concurrently, preoperative medication strategies shifted from glucocorticoid‐dominant therapy toward wider use of csDMARDs and bDMARDs/tsDMARDs.
Wang X +7 more
europepmc +2 more sources
Analysis of gut microbiota in rheumatoid arthritis patients. Disease-related dysbiosis and modifications induced by etanercept [PDF]
A certain number of studies were carried out to address the question of how dysbiosis could affect the onset and development of rheumatoid arthritis (RA), but little is known about the reciprocal influence between microbiota composition and ...
D'Amelio, R +11 more
core +1 more source
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan +8 more
wiley +1 more source

